Locally in the aneurysmal wall, there was a non-significant 50% increase in TNF protein levels in the ETN-treated AAAs when compared to vehicle-treated (p = 0.11), whereas TNF levels were significantly reduced in XPro1595-treated AAAs compared to ETN treatment (Figure 4A). This evidence concerns the gene TNF and achalasia-alacrima syndrome.